Romosozumab reduces risk of fractures in postmenopausal women


eMediNexus    14 September 2017

In a study of postmenopausal women with osteoporosis who were at high risk for fracture, treatment with monthly subcutaneous romosozumab (210 mg) for a year followed by weekly oral alendronate (70 mg) significantly lowered risk of new vertebral (48%) and nonvertebral (19%) than alendronate alone. These findings are reported September 11, 2017 in the New England Journal of Medicine.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.